Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

stained 24-hour bronchodilation over 52 weeks.

At Day 1, Week 26 and Week 52 of the GLOW2 study, NVA237 significantly improved lung function (measured by mean trough FEV1) compared to placebo (all p<0.001) and results were similar to those seen with OL tiotropium. At Day 1 and Week 12, 26 and 52, the FEV1 area under the curve (AUC) for 0-4 hr, 0-12 hr, 12-24 hr and 0-24 hr for NVA237 was superior to placebo (p<0.05) and numerically greater than OL tiotropium.

Shinichi Tamura, CEO of Sosei:

"GLOW2 data further illustrate the potential benefits of once daily NVA237 for patients with COPD. NVA237 has been submitted for approval in Europe and Japan and we look forward to a decision from EU regulators that is expected in 2012."

The study also demonstrated that NVA237 improved COPD symptoms, quality of life and reduced exacerbations compared to placebo. NVA237 significantly reduced breathlessness (measured by the transition dyspnea index or TDI, p=0.002), improved health-related quality of life (measured by the St George's Respiratory Questionnaire or SGRQ, p<0.001), reduced use of rescue medication (p=0.039), and increased the percentage of days with no daytime symptoms (p<0.05)compared to placebo over 52 weeks.

For these symptomatic and quality of life indicators, results were numerically similar to those observed with OL tiotropium over the same time period. NVA237 also significantly prolonged the time to first exacerbation and significantly reduced the rate of moderate/severe exacerbations versus placebo over 52 weeks (p=0.001); these effects were similar to OL tiotropium (p=0.001).

Throughout the GLOW2 study, NVA237 was well-tolerated with a similar incidence of adverse events to placebo and OL tiotropium. Serious adverse events were reported less frequently with NVA237 (12.6%) than with either placebo (15.4%) or OL tiotropium (15.0%).


'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... June 18, 2013  Recent regulatory and budget challenges ... Education groups at large pharmaceutical companies to effectively educate ... effective use of their new products. With the pressure ... is crucial that these "Med Ed" groups ... To address the changes that are transforming the ...
(Date:6/18/2013)... LEANDRO, Calif. , June 18, 2013  Cataracts ...  According to the American Association of Ophthalmology, aging is ... a clouding of the eye,s natural lens. 22 million ... 2020, as Baby Boomers continue to age, that number ... high tech world of iPhones, iPads, smart-phones and computers, ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... LLC ("Deston") announced today that it is currently exploring its ... Otic Solution ("Auralgan") by the Federal Government and that it ... product. "Despite the recent actions by the ... effective treatment for ear pain and inflammation," said David Preston ...
... N.J., Feb. 25, 2011 ConvaTec, a world-leading developer ... hospital care, today announced a new appointment to its ... Senior Vice President and Chief Quality Officer for ConvaTec ... member of the ConvaTec Executive Committee. McNally will be ...
Cached Medicine Technology:Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 2Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 3Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 4
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... Sun Buick GMC, Moosic, is sponsoring the hole-in-one contest at ... on Thursday, June 20, at Irem Country Club, Dallas, Pennsylvania. ... Verano and will go to the lucky golfer at the ... , The MFHS golf tournament is open to all interested ... crew team for 18 holes. The fee is $125 per ...
(Date:6/18/2013)... 2013 Internationally acclaimed plastic surgeon, ... thebestbreast.com, showcasing his unique approach to breast augmentation. ... his surgical method and highlights the results of ... website, Dr. Tebbetts compares his breast augmentation method ... Tebbetts’ method does not necessitate the use drains, ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... signaling network between two previously unconnected proteins, exposing a ... growth at its starting point. , A team led ... Cancer Center reported the tie between epidermal growth factor ... a protein vital to the first step in DNA ... . , "MCM7 overexpression marks cell proliferation and is ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2
... images offers the possibility of using magnetic resonance imaging ... path of many degenerative brain diseases, report scientists at ... of California, San Francisco. The technique, developed by ... Bruce Miller, MD, clinical director of the UCSF Memory ...
... , TUESDAY, April 10 (HealthDay News) -- Black people with ... cardiac death than whites or other racial groups who suffer ... was true regardless of blacks, other risk factors, such as ... Researchers examined 533 black and 8,660 non-black patients ...
... passed the motor vehicle administration,s vision test may not mean ... found that the frequency and distance at which drivers with ... night was severely reduced, even when the drivers have passed ... are very common and lots of people with these conditions ...
... in low- and middle-income countries, and there is an ... help tackle the disease, states an analysis in CMAJ ... more people than HIV/AIDS, tuberculosis and malaria combined. The ... rise through 2030 of 82% in low- and lower-income ...
... San Diego, CA - The American Society of Pediatric ... April 22, during the 2012 Combined Otolaryngology Spring Meetings ... in San Diego, CA. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Doheny HealthDay Reporter , MONDAY, April 9 ... protect against repeat heart attacks, strokes or other cardiovascular ... surprised at these findings because I assumed that there ... Dr. Seung-Kwon Myung, chief of the carcinogenesis branch of ...
Cached Medicine News:Health News:New MRI technique may predict progress of dementias 2Health News:High Blood Pressure May Be Especially Lethal for Blacks 2Health News:Can a standard vision test predict nighttime driving performance? 2Health News:Scientific session and new research highlights 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: